GOSS Stock Forecast & Price Target

Gossamer Bio Inc. has reported a statistically significant and clinically meaningful improvement of approximately 20–25 meters in six-minute walk distance (6MWD) for its product seralutinib compared to placebo, underscoring its potential in treating pulmonary arterial hypertension (PAH). The seralutinib group achieved an impressive +28.2 meter improvement from baseline, indicating robust efficacy, particularly in prespecified subclass analyses showing over 30-meter improvements in functional class III patients. Furthermore, unlike many existing PAH therapies that exhibit a plateau in benefits, seralutinib has shown sustained improvement over a period of seventy-two weeks across various clinical measures, indicating a strong competitive edge in the therapeutic landscape.

Gossamer Bio Inc's financial outlook is significantly impacted by a drastic reduction in the FY32 total revenue estimate to $324 million from a prior projection of $993 million, indicating a substantial decline in expected performance. The company’s product, seralutinib, has faced setbacks with PROSERA data falling short of market expectations, raising concerns about its registrational path and overall market traction. Additionally, an increase in the discount rate to 40% reflects heightened risk perception, contributing to an adjusted valuation that underscores the challenges Gossamer faces in securing regulatory approval and achieving commercial success.